| Serial Number | 79314001 |
| Word Mark | FEXUCLUE |
| Filing Date | Thursday, May 13, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, November 29, 2022 |
| Registration Number | 6908928 |
| Registration Date | Tuesday, November 29, 2022 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, September 13, 2022 |
| Goods and Services | Pharmaceutical agents affecting digestive organs for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Medicines for treating intestinal disorders; Pharmaceutical preparations in the nature of proton-pump inhibitors for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Medicines for the treatment of gastrointestinal diseases; Medicines for human purposes for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; Ethical medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, June 28, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | DAEWOONG PHARMACEUTICAL CO., LTD. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | DAEWOONG PHARMACEUTICAL CO., LTD. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | DAEWOONG PHARMACEUTICAL CO., LTD. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Friday, November 10, 2023 | NEW REPRESENTATIVE AT IB RECEIVED |
| Wednesday, April 12, 2023 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Tuesday, March 21, 2023 | FINAL DISPOSITION NOTICE SENT TO IB |
| Tuesday, March 21, 2023 | FINAL DISPOSITION PROCESSED |
| Tuesday, February 28, 2023 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, November 29, 2022 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, November 29, 2022 | REGISTERED-PRINCIPAL REGISTER |
| Monday, October 3, 2022 | NOTIFICATION PROCESSED BY IB |
| Tuesday, September 13, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 13, 2022 | PUBLISHED FOR OPPOSITION |
| Wednesday, September 7, 2022 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, September 7, 2022 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, August 24, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, August 9, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, August 2, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, August 1, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, August 1, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, February 28, 2022 | REFUSAL PROCESSED BY IB |
| Friday, February 4, 2022 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, February 4, 2022 | REFUSAL PROCESSED BY MPU |
| Thursday, January 13, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, January 12, 2022 | NON-FINAL ACTION WRITTEN |
| Wednesday, January 12, 2022 | ASSIGNED TO EXAMINER |
| Friday, July 2, 2021 | APPLICATION FILING RECEIPT MAILED |
| Monday, June 28, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, June 25, 2021 | SN ASSIGNED FOR SECT 66A APPL FROM IB |